Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update.
The live webcast will be available on the Codexis Investor Relations website and archived for 90 days; a telephone replay will be available for 48 hours.
Positive
- None.
Negative
- None.
News Market Reaction – CDXS
In the Feb 25 session, CDXS gained 1.36%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.9% during that session. Argus tracked a trough of -9.1% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Conference participation | Positive | +0.8% | Announcement of TD Cowen healthcare conference fireside chat and webcast access. |
| Feb 10 | Quality certification | Positive | -3.1% | ISO 9001:2015 certification for core facilities and quality management systems. |
| Jan 07 | Platform evaluation deal | Positive | -1.2% | Axolabs evaluation agreement for ECO Synthesis oligonucleotide manufacturing platform. |
| Nov 10 | GMP facility lease | Positive | +3.5% | Signing of lease for 34,000 sq ft GMP facility to expand production capacity. |
| Nov 06 | Q3 2025 earnings | Negative | -5.3% | Q3 2025 results with revenue decline, restructuring, and extended cash runway through 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often shows mixed reactions, with some positive operational updates selling off while facility and earnings restructuring news aligned with price moves.
Over the past few months, Codexis has announced several operational milestones. In November 2025, it reported Q3 2025 results with a $37.8M Merck Supply Assurance Agreement, workforce reductions and an extended cash runway through 2027, and also signed a lease for a 34,000 sq ft GMP facility. In early 2026, the company signed an ECO Synthesis® evaluation agreement with Axolabs, obtained ISO 9001:2015 certification, and scheduled conference participation. Today’s earnings-date announcement fits into this pattern of ongoing strategic and operational updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com
